🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07665827
Starting soon Not applicable

Efficacy and Safety of Antihypertensive Treatment With Mobile Stroke Units in Ultra-Early Intracerebral Hemorrhage

NCT07665827 · tracked via the Priya Life Science China tracker
Sponsor
Xuanwu Hospital, Beijing
Phase
Not applicable
Started
2026-06
Last updated
2026-06-24

Condition(s) studied

Nervous System DiseasesCerebrovascular DisordersCardiovascular DiseasesVascular DiseasesHemorrhageIntracranial HemorrhagesCerebral HemorrhageCerebral Hemorrhage, HypertensiveStrokeHemorrhagic Stroke, Intracerebral

Investigational drug(s) / intervention(s)

Mobile Stroke Unit ManagementStandard Management

Mobile Stroke Unit Management: MSU is a specialized stroke ambulance equipped with point of care lab, CT scanner, Telemedicine, enabling rapid diagnosis and prehospital management of acute stroke. Patients with suspected stroke undergo on-board CT imaging. Those diagnosed with intracerebral hemorrhage receive immediate prehospital blood pressure lowering. A standard treatment regime based on intravenous (IV) bolus of 25mg urapidil administered over 1 minute. For those patients initial systolic blood pressure 180, another 25mg urapidil bolus will be given if the systolic blood pressure level persists \>150 after 5 minutes.

Standard Management: A regular ambulance. The standard management by EMS includes Electrocardiographic(ECG)monitoring, blood glucose management, airway, respiration, and blood pressure control, complication management, intravenous access establishment and other emergency measures. Prehospital antihypertensive treatment is administered only in cases of severe hypertension (systolic blood pressure ≥220 mmHg), with blood pressure lowering initiated after in-hospital CT confirmation.

Study summary

MSU-ICH is a prospective, multicenter, Week-wise-randomized, open-label, blinded-endpoint (PROBE) clinical trial comparing ultra-early prehospital blood pressure lowering delivered by a Mobile Stroke Unit (MSU) with standard Emergency Medical Services (EMS) in patients with spontaneous intracerebral hemorrhage.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. History and physical/neurological examination consistent with acute stroke. 2. Age ≥18 years; 3. Time from symptom onset to enrollment \<3 hours (onset defined as last known normal). 4. Systolic blood pressure ≥150 mmHg and ≤220 mmHg; 5. Pre-stroke modified Rankin Scale (mRS) score ≤2; 6. Informed consent obtained from the subject or a legally authorized representative. Exclusion Criteria: 1. Glasgow Coma Scale (GCS) score ≤5. 2. Contraindications to intensive blood pressure lowering, including severe arterial stenosis or high-grade stenotic valvular heart disease. 3. Malignant disease or other serious primary illness with a life expectancy of \<3 months. 4. Current participation in another interventional randomized clinical trial.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Xuanwu Hospital Beijing Beijing Municipality

More Xuanwu Hospital, Beijing trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07665827 on ClinicalTrials.gov ↗ ← All trials in China